🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
GMA
$GMAB.CO
🔒 EuropeGenmab A/S
AVG HISTORICAL GAP
+1.15%
MAX GAP RECORD
+9.99%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $GMAB.CO
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$GMAB.CO
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 05, 2026 Earnings Release 2026-11-05 (AFTER CLOSE (16:00)) | 🔮 UPCOMING 🔒 |
| Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE) |
+5.49%
|
| May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE) |
-3.18%
|
| Feb 17, 2026 Earnings Release 2026-02-17 (AFTER CLOSE) |
-2.74%
|
| Nov 06, 2025 Earnings Release 2025-11-06 (AFTER CLOSE) |
-2.68%
|
| Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE) |
+2.56%
|
| May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE) |
-0.11%
|
| Feb 12, 2025 Earnings Release 2025-02-12 (AFTER CLOSE) |
+3.86%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.9%
Bullish Gaps (6)
Bearish Gaps (5)
Neutral / Flat (3)
📖 Intelligence Summary
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗